DOCSLIB.ORG

Drug Delivery Technology Y

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

* DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries. E-mail: [email protected] r e b Mailing List Rental m e c There are a limited amount of sponsorship opportunities available. Candy Brecht e D Tel: (703) 706-0383 / r Please contact us for more information: e Fax: (703) 549-6057 b E-mail: [email protected] m e v East & Midwest – Victoria Geis • Tel: (703) 212- 7735 o All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety N of artwork, photographs, or manuscripts. Every precaution is taken to ensure accuracy, but publishers cannot accept [email protected] responsibility for the accuracy of information supplied herein or for any opinion expressed. Drug Delivery Technology y g (ISSN 1537-2898) is published 10 times in 2006, January, February, March, April, May, June, July/August, September, o l October, and November/December by Drug Delivery Technology LLC, 219 Changebridge Road, Montville NJ 07045. o n Subscription rates: $99.00 for 1 year in the United States, Canada, and Mexico. $153.00 for 1 year outside the United h West – Warren DeGraff • Tel: (415) 721-0664 c States, Canada, and Mexico. All subscriptions are payable in US funds, drawn on US banks. Send payment to: Drug e T Delivery Technology LLC subscription Department, 219 Changebridge Road, Montville NJ 07045. Single copies (prepaid) y [email protected] $15.00, US, Canada, and Mexico; $24.00 in all other countries. Add $5.00 per order for shipping and handling. r e Periodicals Postage Paid at Montville, NJ 07045-9998 and additional mailing offices. Postmaster: please send address v i l changes to Drug Delivery Technology, 219 Changebridge Road, Montville NJ 07045. All rights reserved under the U.S., e D International and Pan-American Copyright Conventions. All rights reserved. No part of this publication may be g International - Ralph Vitaro • Tel: (973) 263-5476 reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopy, recording, u r or information storage and retrieval system, without written permission from the publisher. Authorization to photocopy D [email protected] items for internal or personal use, or the internal or personal use of specific clients, is granted by Drug Delivery Technology LLC for libraries and other users registered with the Copywrite Clearance, 222 Rosewood Drive, Danvers, MA 01923; phone: (978) 750-8400, fax: (978) 750-4470. 4 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 5 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 6 Company Profiles 12 For each participating company, this section presents a special 2-page spread featuring core technologies, capabilities, products, and services as well as visuals and complete contact information. Featured companies include: 3M Drug Delivery Dow Chemical Lipocine Systems DPT Labs Therapeutics Aveva DDS DSM Pharmaceuticals Nektar Therapeutics Azopharma Empi NOF Corporation BD Eurand PharmaCircle Bilcare Global Evonic PharmaForm Clinical Supplies Glatt Pharmaceutical Services Remmele Bilcare Research Engineering Hovione Capsugel Scolr Pharma, Inc InnerCap Technologies Catalent Pharma Xcelience Solutions Partnerships, Technologies & Pipeline Report 58 This Report, divided into four sections for Drug Delivery, Excipient, 0 1 o N Contract Services, and Machinery & Laboratory Equipment & Software, 7 l provides a checklist of currently marketed technologies or services and o V their applications, pipeline/investigational technologies and their 7 0 0 2 applications and stage of development, and partnerships. Technologies r e b include: m e c e Oral Gene Therapy Rectal D / r e b m Inhalation Mucosal Vaginal e v o N Transdermal Capsules Colon y g o l o Parenteral Intranasal Liposomes n h c e T Implants Polymers Lipids y r e v i l e Nasal Biomaterials Devices D g u r D Topical Proteins & Peptides Ocular Transmucosal Controlled Release Excipients 6 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 7 * DDT Nov-Dec2007Working11/9/072:40PMPage8 8 Drug Delivery Technology November/December 2007 Vol 7 No 10 4-color visuals and contact information. contact and 4-color visuals dynamic featuring devices, and services, technologies, emerging and innovative examines Report,thissection Special and Profiles Company the complement To 102 Showcase Technology * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 9 * DDT Nov-Dec 2007 Working 11/9/07 2:41 PM Page 10 Dan Marino, MSc Executive Editorial Director Drug Delivery Technology Shaukat Ali, PhD, MSc John A. Bermingham Der-Yang Lee, PhD Technical Service Manager President & CEO Research Fellow, R&D BASF Pharma Solutions The Lang Companies Technology, R&D Labs McNeil Consumer Healthcare, Johnson & Johnson Sarath Chandar, MBA Derek G. Hennecke, MBA Gary W. Cleary, PhD, Vice President, Global President & CEO PharmD, MBA Marketing & Commercial Xcelience President & CTO Development Corium International SPI Pharma Marc J. Kirchmeier, PhD James N. Czaban, JD John Fraher Associate Director, Partner, FDA Department President, North America Pharmaceutical R&D WilmerHale Eurand Biologicals & Vaccines Merck Research Laboratories Philip Green, PhD Keith Horspool, PhD Ali Rajabi-Siahboomi, Director of Business Director, Research PhD Development Formulations Global Technical Director, Modified Release Advanced Drug Delivery Pfizer Global Research & Technologies Development BD Colorcon David Monteith, PhD, MBA Uday B. Kompella, PhD James W. McGinity, PhD Senior Director, Drug Associate Professor of Professor of Pharmaceutics Delivery & Life Cycle Pharmaceutics University of Texas at Austin Development University of Nebraska Schering-Plough Medical Center 0 1 o N 7 Nasser Nyamweya, PhD James S. Bernstein, Philip L. Smith, PhD l o Technical Service Manager PhD Investment Manager V Degussa President S.R. One, Limited, 7 0 Live Oak Pharmaceutical 0 GlaxoSmithKline 2 Consulting, Inc. r e b m e c e D / r Ronald L. Smith, PhD e Cornell Stamoran Tom Tice, PhD b Director of Exploratory VP, Strategy & Business Executive Vice President m e Biopharmaceutics & v Process and Chief Scientific Officer o N Drug Delivery Catalent Pharma Brookwood y Bristol-Myers Squibb Solutions Pharmaceuticals g o l Research Institute o n h c e T y r e v James Vaughan Beth A-S. Brown, PhD, MS Henry Y. Wu, PhD, MS i l e Division Vice President Senior Manager, Director D g 3M Drug Delivery New Technology u Merck Research r D Systems CIMA LABS, INC. Laboratories 10 * DDT Nov-Dec 2007 Working 11/9/07 2:41 PM Page 11 * DDT Nov-Dec 2007 Working 3.qxd 11/9/07 5:59 PM Page 12 3M DRUG DELIVERY SYSTEMS 3M Center, Bldg. 275-3E-10 St. Paul, Minnesota 55144-1000 T: (800) 643-8086 • F: (651) 737-5265 Website: www.3M.com/DDS 3M Drug Delivery Systems is a global leader and innovator for inhalation and transdermal drug delivery. Between drug discovery and commercialization, 3M Drug Delivery Systems offers… • Innovative and proven technology • Product development services • Global regulatory expertise • Commercial manufacturing • Broad range of customizable system components Our technology, expertise and experience can provide pharmaceutical and biotech companies with: • Differentiated products • Speed to market • Increased probability of technical and commercial success 3M’s proven track record includes development of the first metered-dose inhaler (MDI), development of the first HFA MDI, and the development of the first stand-alone 7-day transdermal system. Products manufactured by 3M Drug Delivery Systems are currently sold in more than 60 countries on six continents. 0 1 o N We combine the agility of a leading drug delivery company with the resources of a major, multinational 7 l corporation. 3M provides expertise in product development, regulatory and manufacturing to enable you o V to get to market sooner. 7 0 0 2 r e Our expertise increases your opportunity for success. www.3m.com/dds b m e c e D / r e b m e v o N y g o l o n h c e T y r e v i l e D g u r D 12 * DDT Nov-Dec 2007 Working 3.qxd 11/9/07 5:59 PM Page 13 * DDT Nov-Dec 2007 Working 3.qxd 11/9/07 5:59 PM Page 14 AVEVA DRUG DELIVERY SYSTEMS INC.
Recommended publications
  • Progress Report January 2009 – December 2011

    Progress Report January 2009 – December 2011

    North Carolina State University Professional Science Master’s Program Progress Report January 2009 – December 2011 The Graduate School College of Agriculture & Life Sciences College of Design College of Education College of Engineering College of Humanities & Social Sciences Poole College of Management College of Natural Resources College of Physical & Mathematical Sciences College of Textiles College of Veterinary Medicine First-Year College 1 Greetings From the UNC System PSM Director The Professional Science Master’s (PSM) Program is one of the University of North Carolina (UNC) System’s ways to close the existing skills gap in the workplace. Together with local employers, we design graduate education and training regimens to match employers’ needs. The UNC System has undertaken a collaborative effort to develop these new programs in key areas of importance to North Carolina’s local economies. I am pleased to report that NC State University now offers nine PSM programs. Several new programs are at various planning stages, and numerous new central resources and services are available or under way for these programs. A special milestone in 2010 was the establishment of the PSM Council at NC State University. Members of this group include faculty who direct PSM programs or are planning to offer them in the future. The PSM Council oversees new program development and determines the future strategy for the PSM programs at NC State University. Another important milestone was the award of a new UNC System grant from the Alfred P. Sloan Foundation and support from the UNC General Administration for multiple online tools. I am greatly indebted to the many employers, professors and students who contribute to the collective success of NC State University’s PSM programs.
  • PIIS0016508516348168(1).Pdf

    PIIS0016508516348168(1).Pdf

    Gastroenterology 2016;151:651–659 CLINICAL—LIVER High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis Edward Gane,1 Fred Poordad,2 Stanley Wang,3 Armen Asatryan,3 Paul Y. Kwo,4 Jacob Lalezari,5 David L. Wyles,6 Tarek Hassanein,7 Humberto Aguilar,8 Benedict Maliakkal,9 Ran Liu,3 Chih-Wei Lin,3 Teresa I. Ng,3 Jens Kort,3 and Federico J. Mensa3 1University of Auckland, Auckland, New Zealand; 2Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas; 3AbbVie, Inc, North Chicago, Illinois; 4Indiana University School of Medicine, Indianapolis, Indiana; 5Quest Clinical Research, San Francisco, California; 6University of California San Diego, La Jolla, California; 7Southern California GI and Liver Centers and Southern California Research Center, Coronado, California; 8Louisiana Research Center, Shreveport, Louisiana; 9University of Rochester Medical Center, Rochester, New York to liver decompensation, as defined by ascites, jaundice, See Covering the Cover synopsis on page 571; encephalopathy, or variceal bleeding.2 Achievement of a CLINICAL LIVER see editorial on page 587. sustained virologic response (SVR) reduces the risk of hepatic decompensation events, end-stage liver disease, 3–5 BACKGROUND & AIMS: The combination of ABT-493 (NS3/4A hepatocellular carcinoma, and liver-related mortality. protease inhibitor) plus ABT-530 (NS5A inhibitor) has shown Recognizing the need to prevent these complications, the high rates of sustained virologic response at post-treatment American Association for the study of Liver Diseases/ week 12 (SVR12) in noncirrhotic patients infected with hepa- Infectious Disease Society of America, and the European titis C virus (HCV) genotypes (GTs) 1–6.
  • Radius Health, Inc

    Radius Health, Inc

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 RADIUS HEALTH, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials: ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount previously paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: April 20, 2018 To Our Stockholders: You are cordially invited to attend the 2018 Annual Meeting of Stockholders of Radius Health, Inc.
  • 4Oct200722045121 1Dec200517045043

    4Oct200722045121 1Dec200517045043

    4OCT200722045121 This prospectus (the ‘‘Prospectus’’) relates to the initial offering (the ‘‘Offering’’) to subscribe for up to A75 million of new common shares in Ablynx NV (the ‘‘Company’’ or ‘‘Ablynx’’), with VVPR strips (the ‘‘VVPR Strips’’). This amount of New Shares with VVPR Strips may be increased by up to 15 per cent, to an amount of A86.25 million (the ‘‘Increase Option’’, the new shares initially offered and the shares offered as a result of the possible exercise of the Increase Option jointly being referred to as the ‘‘New Shares’’). Any decision to exercise the Increase Option will be announced, at the latest, on the date the Offer Price is announced. JPMorgan and KBC Securities (the ‘‘Joint Global Coordinators’’) will be granted an over-allotment option by the Company (the ‘‘Over-allotment Option’’), exercisable as of the listing date (the ‘‘Listing Date’’) and until 30 days thereafter, corresponding to up to 15 per cent of the New Shares subscribed for in the Offering for the sole purpose of allowing the Joint Global Coordinators to cover over-allotments, if any. The existing shares covered by the Over-allotment Option (the ‘‘Additional Shares’’ and, together with the New Shares, the ‘‘Offered Shares’’) and the New Shares issued upon exercise of the Over-allotment Option, if any, will not have a separate VVPR Strip. The Offered Shares are offered to the public in Belgium (including to employees, consultants and independent directors of the Company in Belgium) and, pursuant to a private placement, to institutional investors, both within and outside Belgium and to employees, consultants and independent directors of the Company outside Belgium.
  • Chemosaturation with Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases Evan S

    Chemosaturation with Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases Evan S

    Special Report Chemosaturation With Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases Evan S. Glazer, MD, PhD, and Jonathan S. Zager, MD Background: In patients with hepatic metastases from solid-organ malignancies, surgical resection may be a potentially curative option, but it is not possible in most cases. Chemosaturation with percutaneous hepatic perfusion was developed for the management of unresectable metastases to the liver. Methods: Relevant medical literature was summarized with regard to the outcomes and limitations of che- mosaturation with percutaneous hepatic perfusion. Results: Six articles were identified that contained data on 91 individuals who received chemosaturation with percutaneous hepatic perfusion. More than 60% of these study patients were diagnosed with ocular melanoma. The overall response rate was 48% and the rate of disease control was 90%. Chemosaturation with percutaneous hepatic perfusion improved the rates of overall and hepatic progression-free survival (PFS). The data are limited but suggest that the rate of PFS was improved in study patients with isolated melanoma hepatic metastases who received chemosaturation with percutaneous hepatic perfusion compared with those assigned to standard care. Conclusions: Our results suggest that chemosaturation with percutaneous hepatic perfusion produces favor- able tumor response rates in select individuals with unresectable hepatic metastases from multiple primary cancers, particularly ocular and cutaneous melanomas. Data from a single randomized
  • DDT Cover/Back April 2006.Qx

    DDT Cover/Back April 2006.Qx

    June 2007 Vol 7 No 6 www.drugdeliverytech.com IN THIS ISSUE INTERVIEW WITH EURAND’S CHIEF COMMERCIAL OFFICER MR. JOHN FRAHER The eFlow® Nebulizer 30 Shabtai Bauer, PhD Markus Tservistas, PhD Bioadhesive Microspheres 54 Jayvadan Patel, PhD Transdermal Solutions 68 Gary W. Cleary, PhD FEATURING Imaging CROs 72 Richard Taranto Autoimmune The science & business of specialty pharma, biotechnology, and drug delivery Diseases 80 Douglas Kerr, MD Adam Kaplin, MD JuliaJulia Rashba-Rashba- Shaukat Ali, Richard Step,Step, PhDPhD PhD Sitz, MBA EfEfficientficient PulmonaryPulmonary HMW Povidone Beyond Sticky Partnering With DeliveryDelivery ofof BiologicalBiological PolymerPolymer-Based-Based toto Sophisticated:Sophisticated: NovaQuest 84 MoleculesMolecules asas Films for The Many PROMAXXPROMAXX Fast-Dissolving Dimensions Ms. Cindy H. Dubin MicrMicrospheresospheres Drug Delivery of Adhesives June 2007 Vol 7 No 6 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel:
  • Life Sciences Industry Wake County * Research Triangle Index of Featured Organizations Contract Research Contract Manufacturer 48

    Life Sciences Industry Wake County * Research Triangle Index of Featured Organizations Contract Research Contract Manufacturer 48

    LIFE SCIENCES INDUSTRY WAKE COUNTY * RESEARCH TRIANGLE INDEX OF FEATURED ORGANIZATIONS Contract Research Contract Manufacturer 48. Kurve Technology, Inc. ...............................D4 49. LaamScience, Inc. ...............................C4, I10 1. A10 Clinical Solutions, Inc. ........................E5 71. Accurate Machine and Tool Co. .................E8 50. LipoScience, Inc. ........................................C7 2. AAIPharma, Inc....................................C4, I11 72. Better Medicines, LLC ................................C3 51. Mardil, Inc. ..................................................D4 3. Alpha-Gamma Technologies, Inc. ..............D7 73. Merck BioManufacturing Network .............D4 52. MDxHealth, Inc. ................................... B3, G9 4. Analytical Solutions, Inc. ..................... C3, H9 74. Nortech Systems 53. Med-El Corp. ..................................... B3, G10 5. Appealing Products, Inc. ............................E6 (Formally TriVirix International) ..................A3 54. MedFaxx, Inc. .............................................A8 6. BIoCI Systems, Inc. ....................................D8 75. Patheon, Inc. .......................................C4, I11 55. Medisim USA .............................................. F5 7. BioLink Life Sciences, Inc. .........................D4 76. Rockwell Automation Life Sciences ...........E4 56. Medis Medical Imaging Systems, Inc. ........C7 8. Burleson Research Technologies ..............C4 77. Stainless Steel Fabrications .......................D7
  • Drug Delivery Technology

    Drug Delivery Technology

    * DDT Nov-Dec 2006 Round 5 11/10/06 7:20 PM Page 2 November/December 2006 Vol 6 No 10 IN THIS ISSUE Corporate Profiles 16 Drug Delivery Technologies 73 Excipients, Polymers, Liposomes & Lipids 90 Contract Pharmaceutical & Biological Development Services 96 Machinery & Laboratory Equipment and Software 109 Technology Spotlight 114 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 3 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 4 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 5 November/December 2006 Vol 6 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Fax: (703) 548-3733 E-mail: [email protected] E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] International Ralph Vitaro 219 Changebridge Road Vol 6 No 10 Montville, NJ 07045 Tel: (973) 299-1200 Fax: (973) 299-7937 E-mail: [email protected] Mailing List Rental Candy Brecht Tel: (703) 706-0383 Fax: (703) 549-6057 E-mail: [email protected] All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety November/December 2006 of artwork, photographs, or manuscripts.
  • Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results

    Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results

    Source: Delcath Systems, Inc. July 28, 2021 09:00 ET Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: August 10, 2021 Time: 8:30 AM Eastern Time Toll Free: 877-545-0523; Entry Code: 148562 International: 973-528-0016; Entry Code: 148562 The call will also be available over the Internet and accessible at: https://www.webcaster4.com/Webcast/Page/2475/42376 About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA). In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.
  • Happy-Healthy-Hormones-Latest.Pdf

    Happy-Healthy-Hormones-Latest.Pdf

    HAPPY HEALTHY HORMONES Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE HAPPY HEALTHY HORMONES Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE This book has been written and published to provide information and should not be used as a substitute for the recommendations of your health care professional. Be- cause each person and medical situation are unique, the reader is urged to review this information with a qualified health professional. You should not consider the infor- mation contained in this text to represent the practice of medicine or to replace consultation with a physician or other qualifiedhealth care provider. The Menopause Method, Inc. Sarasota, Florida 941-366-3768 www.menopausemethod.com [email protected] The Menopause Method: A Woman’s Guide to Navigating Menopause, sixth edition, 2017. Copyright © 2001, 2002, 2006, 2007, 2014, 2017 by Daved Rosensweet M.D. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photo- copying, recording, or otherwise, without the prior written permission of the copyright owner. Sixth Edition 2017 ISBN: 9780999744901 Published in the United States of America Dedication This book is dedicated, first and foremost, to my patients in menopause: for 24 years, woman by woman, moment by moment, molecule by molecule, you have given me what has culminated in these pages. You know who you are, and I do thank you. Writing this dedication has turned out to be a deep and heartfelt experience for me.
  • Delcath Systems, Inc

    Delcath Systems, Inc

    Delcath Systems, Inc. Corporate Presentation (NASDAQ: DCTH) August 2020 Forward-looking Statements This presentation contains forward-looking statements, which are subject to certain risksand uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company’s clinical trials including without limitation the OM and ICC clinical trial programs, timely enrollment and treatment of patients in the global Phase 3 OM and ICC Registration trials, IRB or ethics committee clearance of the Phase 3 OM and ICC Registration trial protocols from participating sites andthe timing of site activation and subject enrollment in each trial, the impact of the presentations at major medical conferences and future clinical results consistent with the data presented, the Company’s ability to successfully commercialize the Melphalan HDS/CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the impact of the Company’s exclusive licensing agreement with medac on commercial adoption in Europe and resulting revenue, if any, the Company’s ability to successfully enter into other strategic partnerships and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, and uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities.
  • Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, And

    Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, And

    ANTICANCER RESEARCH 33: 1989-2000 (2013) Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, and Gastric Cancer Cell Lines in a Short-term Exposure Model of Chemosaturation Therapy by Percutaneous Hepatic Perfusion RAJNEESH P. UZGARE, TIMOTHY P. SHEETS and DANIEL S. JOHNSTON Pharmaceutical Research and Development, Delcath Systems, Inc., Queensbury, NY, U.S.A. Abstract. Background: The goal of this study was to candidates for use in the CS-PHP system to treat patients determine whether liver, gastric, or colonic cancer may be with gastric and colonic metastases, and primary cancer of suitable targets for chemosaturation therapy with the liver. percutaneous hepatic perfusion (CS-PHP) and to assess the feasibility of utilizing other cytotoxic agents besides Chemotherapeutic molecules exert beneficial clinical effects melphalan in the CS-PHP system. Materials and Methods: by inhibiting cell growth or by inducing cell death via Forty human cell lines were screened against three cytotoxic apoptosis. They can be divided into several categories based chemotherapeutic agents. Specifically, the dose-dependent on their mechanisms of action. The chemotherapeutic agent effect of melphalan, oxaliplatin, and paclitaxel on melphalan hydrochloride, which has been approved by the proliferation and apoptosis in each cell line was evaluated. US Food and Drug Administration and is used in the These agents were also evaluated for their ability to induce treatment of multiple myeloma and ovarian cancer, is a apoptosis in normal primary human hepatocytes. A high- derivative of nitrogen mustard that acts as a bifunctional dose short-term drug exposure protocol was employed to alkylating agent. Melphalan causes the alkylation of DNA at simulate conditions encountered during CS-PHP.